no need to worry, page-15

I agree with meerkat, that AHZ is overvalued at current prices. AHZ is a company with a 159m market cap, with revenue of around 7m and no earnings.
Biotechs are difficult to value as the hype in the story is factored into the valuation pushing the price up. IMO, it's nearly impossible to put a true value here as clinical trials, approvals, and then getting the product to market are all costly expenses, and if things take longer than anticipated, costs can blowout very quickly.
Having said that, I am happy to allocate a small proportion of my portfolio to AHZ in anticipation that management deliver, and on time, as they have in the past. Cardiocel is proven, and hopefully the uptake appreciates, but if the herpes vaccine comes through, the game is on for AHZ.